ShareProphets


The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join ShareProphets at less than 2p per article

> All the big AIM fraud exposés

> 300 articles and podcasts a month

> Hot share tips

> Original investigations by our experienced team

> No ads, no click-bait, no auto-play videos

Find out more

Optibiotix - not blockbuster news, but good…patience my friends

By Tom Winnifrith | Wednesday 5 December 2018


Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Optibiotix (OPTI) boss Steve O’Hara has dusted down his Adam Reynolds keyboard for another RNS which the market seems, unwisely to ignore. But we, the faithful shareholders, will be rewarded for our patience with something far more stirring and we shouldn’t be waiting very long at all.

The latest news is that O’Hara has signed a three year distribution deal for Slimbiome as a medical device for Greece and Cyprus with an option to take on the Middle East as well. We are told the, un-named, company has an established distribution network in Cyprus, Greece and the Middle East and a track record in taking new products to market direct to pharmacies through its established distribution network. It is associated with a number of private clinics providing therapies to individuals across the world.

But for some bollockese reason we are not allowed to know the name of this company which now has an exclusive license. The Nomad will have seen the contract and knows it is real but we have to invest in the dark. What we do know is that the Bubbles have placed an early order and expect to make more orders ahead of a launch in early 2019. So more revenues for Optibiotix. That is good news.

The market is demanding more than releases typed on the Adam Reynolds keyboard and that is why the shares are off a tad. But I am very confident that we will see releases typed on O’Hara’s own PC - which has numbers - very soon and that those numbers will impress even hardened cynics. That will drive the shares sharply higher and thus the stance is a VERY STRONG HOLD with a short term target to sell or top slice of at least 125p.

Show patience, Steve O’Hara could well be funding Santa this year.

This article first appeared on the N50 website which Tom Winnifrith runs with Steve Moore & Lucian Miers. To access the website ahead of the next share tip from Tom & Steve and a new shorting piece from Lucian shortly click HERE


Filed under:


Never miss a story.




This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.


More on OPTI


Comments

Comments are turned off for this article.


Site by Everywhen